dovitinib + imatinib

Dovitinib (TKI258) is a multikinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) 1–3, fibroblast growth factor receptors (FGFRs) 1–3, fetal liver tyrosine kinase receptor 3 (FLT3), PDGFRβ, and KIT. Imatinib is a tyrosine kinase inhibitor primarily targeting BCR-ABL fusion protein and KIT/PDGFRA in gastrointestinal stromal tumors (GIST). The combination of dovitinib and imatinib has not been widely studied as a standard regimen; however, both drugs are used in the treatment of advanced GISTs after failure of prior therapies. Dovitinib has shown modest antitumor activity with manageable toxicities in heavily pretreated patients with advanced GISTs[1]. Imatinib revolutionized the treatment of GIST and certain leukemias by specifically inhibiting abnormal kinases driving tumor growth[4][8]. There is no established brand or unique name for this combination.

Brand names

Gleevec

Other names

Dovitinib lactate + imatinib mesylateDovitinib and Imatinib combination